Extended Release Olanzapine (Zyprexa Relprevv®) is a long-acting, second-generation (atypical), injectable antipsychotic. Here is basic information about this medication.

FDA-approved indications

Schizophrenia

Dosage

Recommended dosing of extended release olanzapine based on correspondence to oral olanzapine doses

A. First 8 weeks of treatment
a) Target oral dose 10 mg/day: 210 mg/2 weeks or 405 mg/4 weeks
b) Target oral dose 15 mg/day: 300 mg/2 weeks
c) Target oral dose 20 mg/day: 300 mg/2 weeks

B. Maintenance dose after 8 weeks
a) Target oral dose 10 mg/day: 150 mg/2 weeks or 300 mg/4 weeks
b) Target oral dose 15 mg/day: 210 mg/2 weeks or 405 mg/4 weeks
c) Target oral dose 20 mg/day: 300 mg/2 weeks

Note: Zyprexa Relprevv is not approved for the treatment of dementia related psychosis in elderly due to increased risk of death and cerebrovascular accidents.

General Instructions

1. Zyprexa Relprevv® is intended for deep intramuscular gluteal injection only and should not be administered intravenously or subcutaneously.
2. Establish tolerability with oral olanzapine prior to initiating treatment.
3. Must be suspended only in the diluent provided in the convenience kit.
4. Use in specific populations (including renal and hepatic impaired, and pediatric population) has not been studied.

Please refer to Prescribing Information (see link below) for complete discussion of dosage, administration, warnings and precautions, contraindications, etc.

Dosage forms and strengths

Powder for suspension (for IM use only): 210 mg/vial, 300 mg/vial, and 405 mg/vial